Somewhat Positive Press Coverage Somewhat Unlikely to Affect Enzo Biochem (ENZ) Share Price
Media stories about Enzo Biochem (NYSE:ENZ) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Enzo Biochem earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 45.8013485302562 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Enzo Biochem, Inc. – Value Analysis (NYSE:ENZ) : August 25, 2017 (finance.yahoo.com)
- Enzo Biochem, Inc. ($0.01 Par (NYSE:ENZ) Sees Significantly Higher Trading Volume – Highlight Press (highlightpress.com)
- Enzo Biochem, Inc. ($0.01 Par (NYSE:ENZ) Experiences Heavier than Usual Trading Volume – Highlight Press (highlightpress.com)
- ALLETE Inc (ALE) and Enzo Biochem Inc (ENZ) Seeing Needle Moving This Session – Evergreen Caller (evergreencaller.com)
- Latin America Biomarkers Market By Type and Size| Industry Report 2015-2020 (emailwire.com)
Enzo Biochem (ENZ) traded up 0.54% during midday trading on Thursday, reaching $11.24. 105,782 shares of the company traded hands. The company has a market cap of $521.61 million, a price-to-earnings ratio of 15.76 and a beta of 0.97. The company has a 50-day moving average price of $11.21 and a 200-day moving average price of $9.25. Enzo Biochem has a 12-month low of $4.88 and a 12-month high of $12.04.
Several equities research analysts recently weighed in on ENZ shares. Zacks Investment Research downgraded shares of Enzo Biochem from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. BidaskClub downgraded shares of Enzo Biochem from a “hold” rating to a “sell” rating in a report on Monday, August 14th.
WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/31/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-enzo-biochem-enz-share-price.html.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.